Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial

Lone Petersen, Anne Thorup, Johan Øqhlenschlaeger, Torben Øqstergaard Christensen, Pia Jeppesen, Gertrud Krarup, Per Jørrgensen, Erik Lykke Mortensen, Merete Nordentoft, Lone Petersen, Anne Thorup, Johan Øqhlenschlaeger, Torben Øqstergaard Christensen, Pia Jeppesen, Gertrud Krarup, Per Jørrgensen, Erik Lykke Mortensen, Merete Nordentoft

    74 Citations (Scopus)

    Abstract

    OBJECTIVE: To examine the frequency and predictors of good outcome for patients with first-episode schizophrenia spectrum disorder (SSD). METHOD: We conducted a 2-year follow-up of a cohort of patients (n = 547) with first-episode SSD. We evaluated the patients on demographic variables, diagnosis, duration of untreated psychosis (DUP), premorbid functioning, psychotic and negative symptoms, substance abuse, adherence to medication, and service use. ORs were calculated with logistic regression analyses. RESULTS: A total of 369 patients (67%) participated in the follow-up interview. After 2 years, 36% remitted and 17% were considered fully recovered. Full recovery was associated with shorter DUP, better premorbid adjustment, fewer negative symptoms at baseline, no substance abuse at baseline, and adherence to medication and OPUS treatment. CONCLUSIONS: Several predictive factors were identified, and focus should be on potentially malleable predictors of outcome, for example, reducing DUP and paying special attention to patients who are unlikely to achieve good outcome, for example, patients with a substance abuse problem and poor premorbid adjustment.
    Original languageEnglish
    JournalCanadian Journal of Psychiatry
    Volume53
    Issue number10
    Pages (from-to)660-70
    Number of pages11
    ISSN0706-7437
    Publication statusPublished - 2008

    Fingerprint

    Dive into the research topics of 'Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial'. Together they form a unique fingerprint.

    Cite this